Phase 2 Study of TLK286 in Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- Registration Number
- NCT00035841
- Lead Sponsor
- Telik
- Brief Summary
The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Histologic diagnosis of breast cancer
- Metastatic disease
- Measurable or evaluable disease
- No prior chemotherapy regimens
- Age at least 18 years
- Adequate liver and kidney function
- Adequate bone marrow function
Exclusion Criteria
- Pregnant or lactating women
- Unstable medical conditions
- Chemotherapy within 14 days of TLK286
- Radiation therapy within 14 days of TLK286
- Hormonal therapy within 14 days of TLK286
- Immunotherapy within 14 days of TLK286
- CNS metastasis unless controlled by treatment
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
Indiana University Medical Center
🇺🇸Indianapolis, Indiana, United States
Cleveland Clinic Taussig Cancer Center
🇺🇸Cleveland, Ohio, United States
Arizona Cancer Center🇺🇸Tucson, Arizona, United States